Pneumocystis carinii is a major opportunistic pathogen of immunocompromised patients. Because P. carinii cannot be reliably cultured, molecular approaches have been utilized to identify and characterize antigens of this organism. Recombinant antigens can then be used to examine host immune responses to P. carinii infections. We have an ongoing project to characterize the antigens of both rat and human P. carinii. We have previously purified the major surface glycoprotein (MSG) of both rat and human pneumocystis using HPLC. It is necessary to use P. carinii from both sources because antigenically they are different and specifically the major surface antigen in rat and human P. carinii are clearly different. Subsequently, we identified a number of clones from a cDNA library of rat P. carinii that contain genes encoding for the MSG. These clones are clearly related but not identical, demonstrating that multiple genes encode the MSG. We have continued studies to characterize potential antigens of P. carinii genes. We have cloned a number of human P. carinii MSG genes and have produced a recombinant fragment encoding a highly conserved region of human P. carinii MSGs that can be expressed at high levels. Preliminary studies have demonstrated that most humans have antibodies to the recombinant peptide, supporting the hypothesis that most humans have been previously infected with P. carinii. Over the past year we have expressed a full-length MSG in two fragments. We are currently attempting to purify these fragments, and will then use them in ELISA assays. We ultimately plan to use this panel of recombinant peptides to examine cellular and antibody responses to P. carinii in healthy and immunocompromised patients. In addition, we have begun studies to characterize other P. carinii antigens. We have identified two families of genes related to the MSG whose expression is regulated differently from MSG genes. We have also identified a family of genes in rat P. carinii, encoding proteases related to the yeast kexin, which functions as a pro-protein processing enzyme. This protease appears to be expressed on the surface of rat P. carinii. The goal of this study is to better understand the pathogenesis of P. carinii pneumonia with the hope that we can use this information to control or prevent this disease.

Agency
National Institute of Health (NIH)
Institute
Clinical Center (CLC)
Type
Intramural Research (Z01)
Project #
1Z01CL000037-13
Application #
6431756
Study Section
(CCM)
Project Start
Project End
Budget Start
Budget End
Support Year
13
Fiscal Year
2000
Total Cost
Indirect Cost
Name
Clinical Center
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Kutty, Geetha; Maldarelli, Frank; Achaz, Guillaume et al. (2008) Variation in the major surface glycoprotein genes in Pneumocystis jirovecii. J Infect Dis 198:741-9
Burbelo, Peter D; Ching, Kathryn H; Mattson, Thomas L et al. (2007) Rapid antibody quantification and generation of whole proteome antibody response profiles using LIPS (luciferase immunoprecipitation systems). Biochem Biophys Res Commun 352:889-95
Beard, Charles Ben; Roux, Patricia; Nevez, Gilles et al. (2004) Strain typing methods and molecular epidemiology of Pneumocystis pneumonia. Emerg Infect Dis 10:1729-35
Kutty, G; Ma, L; Kovacs, J A (2001) Characterization of the expression site of the major surface glycoprotein of human-derived Pneumocystis carinii. Mol Microbiol 42:183-93
Russian, D A; Andrawis-Sorial, V; Goheen, M P et al. (1999) Characterization of a multicopy family of genes encoding a surface-expressed serine endoprotease in rat Pneumocystis carinii. Proc Assoc Am Physicians 111:347-56
Huang, S N; Angus, C W; Turner, R E et al. (1999) Identification and characterization of novel variant major surface glycoprotein gene families in rat Pneumocystis carinii. J Infect Dis 179:192-200